Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2018’, provides in depth analysis on Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Metabolic Disorders, Ophthalmology, Cardiovascular, Dermatology, Gastrointestinal and Infectious Disease under development targeting Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

– The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects

– The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Factor Therapeutics Ltd

Merck & Co Inc

SciFluor Life Sciences LLC

SOM Biotech SL

Vascular Pharmaceuticals Inc

VDDI Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Companies Involved in Therapeutics Development

Factor Therapeutics Ltd

Merck & Co Inc

SciFluor Life Sciences LLC

SOM Biotech SL

Vascular Pharmaceuticals Inc

VDDI Pharmaceuticals

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Drug Profiles

A-11 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-0429 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSP-68 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-200 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proagio Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RUC-4 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0166 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-0777 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetraiodothyroacetic acid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-2690B Drug Profile

Product Description

Mechanism Of Action

R&D Progress

xemilofiban Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Dormant Products

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Discontinued Products

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Product Development Milestones

Featured News & Press Releases

Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration

Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Nov 02, 2017: VF001002 Clinical Trial Update: Strong performance in October driven by new sites

Sep 28, 2017: SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients

May 22, 2017: Factor Therapeutics Appoints Dr. Rosalind Wilson as CEO

May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200

Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update

Dec 20, 2016: Factor Therapeutics First Patient In and Clinical Update

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)

Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution

Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US

Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board

Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases

May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Factor Therapeutics Ltd, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by SciFluor Life Sciences LLC, H1 2018

Pipeline by SOM Biotech SL, H1 2018

Pipeline by Vascular Pharmaceuticals Inc, H1 2018

Pipeline by VDDI Pharmaceuticals, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports